Razelle Kurzrock, Founding Director of Michels Rare Cancers Research Laboratories at the Medical College of Wisconsin and Co-Founder and Board Member at CureMatch, shared Vivek Subbiah’s post on X, adding:
“Our commentary and implications for future precision studies. Really important— operationalizing is critical.”
Quoting Vivek Subbiah’s post:
“Pleased to share our commentary in the Matters arising section of Nature Medicine on “Critical evaluation of the ProfiLER-02 study design and outcomes” – offering our key insights into study design, what worked, what didn’t, and implications for precision oncology.”
Title: Critical evaluation of the ProfiLER-02 study design and outcomes
Authors: Vivek Subbiah and Razelle Kurzrock
Read the Full Article on Nature Medicine
More posts featuring Vivek Subbiah.